ARQT - Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion opportunities in dermatology.
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to
Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine.
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price
WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) insider Masaru Matsuda sold 3,674 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $25.00, for a total value of $91,850.00. Following the sale, the insider directly owned 112,508 shares in the company,
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York.
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Bamco Inc. NY acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,253,120 shares of the company's stock, valued at approximately $32,857,000. Bamco Inc. NY owned
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Deutsche Bank AG bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 382,682 shares of the company's stock, valued at approximately $10,034,000. Deutsche Bank AG owned approximately 0.31% of Arcutis
WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis' common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis' common stock to 24 newly hired employees.
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share a year ago.
Arcutis Biotherapeutics NASDAQ: ARQT reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to rise across approved dermatology indications.